GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Genenta Science S.p.A.
Genenta is an Italian biotech company developing gene therapy for cancer. Its stock price represents a venture capital bet on the success of its technology. The chart reflects news from its clinical trials and the overall sentiment in the biotech sector.
Share prices of companies in the market segment - Oncology cell gene therapy
Genenta Science is a biotech company developing gene therapy for cancer using an approach that modifies blood stem cells to fight tumors. We've classified it in the "Oncology Cell Gene Therapy" segment. The chart below illustrates the overall dynamics of this cutting-edge and complex biotech sector.
Broad Market Index - GURU.Markets
Genenta Science is an Italian biotech company developing gene therapy for cancer. It is a component of the GURU.Markets index. The chart below shows the US market. See how its stock compares to the US market trend.
Change in the price of a company, segment, and market as a whole per day
GNTA - Daily change in the company's share price Genenta Science S.p.A.
Genenta Science S.p.A.'s daily share price fluctuations reflect the extreme volatility inherent in gene therapy companies. This metric measures the sensitivity of the company to clinical trial data for its oncology drugs.
Daily change in the price of a set of shares in a market segment - Oncology cell gene therapy
Genenta Science S.p.A. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with GNTA's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Genenta Science is an Italian biotech company developing gene therapy for cancer. Its US-listed shares bring the dynamism of the European biotech sector to the market. These international factors complicate the overall market volatility picture.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Genenta Science S.p.A.
Genenta Science S.p.A.'s year-over-year performance is a story of gene therapy development for solid tumors. Its 12-month market cap is entirely dependent on early clinical trial data. The success of its approach, which targets the tumor microenvironment, could be a breakthrough in the treatment of difficult-to-treat cancers.
Annual dynamics of market capitalization of the market segment - Oncology cell gene therapy
Genenta Science is a biotech company developing gene therapy for cancer treatment. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the high risks associated with this cutting-edge field of medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Genenta is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its share price (ADR) reflects investor hopes for the success of new cell therapy trials. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Genenta Science S.p.A.
Genenta Science is an Italian biotech company working in the field of cancer gene therapy. Its monthly performance reflects progress in its early clinical trials. Being in the early stages, its valuation is based on expectations and scientific data presented at conferences.
Monthly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Cancer gene therapy is one of the most cutting-edge frontiers in medicine. The dynamics of this biotech sector, as seen in the chart, reflect both the enormous hopes of investors and the high level of uncertainty. Companies like Genenta Science are developing innovative approaches in this area.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Genenta Science, an Italian biotech developing gene therapy, is a venture bet. Its shares are driven by news of trials, and their performance is completely disconnected from overall market trends, which is typical for biotech.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Genenta Science S.p.A.
Shares of Genenta Science, an Italian biopharmaceutical company developing cancer gene therapy, have been experiencing high volatility on a weekly basis. Any news about the progress of clinical trials of its innovative approach provokes a sharp reaction from investors.
Weekly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Genenta Science shares, like those of the entire gene therapy sector, are moving on a backdrop of scientific breakthroughs and investor expectations. Regulatory news is creating extreme volatility for everyone. The chart will show whether the company is leading the hype.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Genenta Science shares, like those of the entire gene therapy sector, are moving on a backdrop of scientific breakthroughs and investor expectations. Regulatory news is creating extreme volatility for everyone. The chart will show whether the company is leading the hype.
Market capitalization of the company, segment and market as a whole
GNTA - Market capitalization of the company Genenta Science S.p.A.
The Genenta Science market capitalization chart is a financial valuation of the Italian biotech company developing gene therapy for cancer. It reflects investor expectations for its unique approach. Its speculative dynamics tell a story about how the market evaluates early-stage science and the risks associated with developing complex drugs.
GNTA - Share of the company's market capitalization Genenta Science S.p.A. within the market segment - Oncology cell gene therapy
Genenta Science is a biotech company developing gene therapies that "train" immune cells to attack tumors. Its market share reflects the potential of its unique approach to cancer treatment. The chart below shows the market's weighting for this innovative Italian company.
Market capitalization of the market segment - Oncology cell gene therapy
Genenta Science is an Italian biopharmaceutical company developing gene therapy for cancer. The chart below shows the overall market capitalization of this entire sector. Its dynamics reflect the global efforts to create "living medicines." Genenta is one of many innovators in this complex field.
Market capitalization of all companies included in a broad market index - GURU.Markets
Gene therapy, seen in the graph, uses viruses to deliver drugs. Genenta Science is developing a cancer treatment that delivers interferon-producing stem cells to tumors. Its capitalization represents a highly risky bet on this complex but potentially powerful approach.
Book value capitalization of the company, segment and market as a whole
GNTA - Book value capitalization of the company Genenta Science S.p.A.
Genenta Science's schedule represents capital for targeted gene therapy for cancer. The company's R&D-stage book value consists of financial reserves. These assets are used to develop an approach that "trains" immune cells to attack tumors by delivering genes directly to the bone marrow.
GNTA - Share of the company's book capitalization Genenta Science S.p.A. within the market segment - Oncology cell gene therapy
Genenta Science, a clinical-stage cell therapy company, holds a minimal stake in the sector, consisting of R&D assets. Its value lies in its unique approach to cancer treatment, rather than in its current large manufacturing base.
Market segment balance sheet capitalization - Oncology cell gene therapy
Genenta Science S.p.A. is a cell therapy company in the R&D stage, making its model intellectually rather than capital-intensive. The company's value lies in its tumor treatment platform. Compared to the entire biotech sector, its "light" balance sheet is typical of companies at the forefront of science.
Book value of all companies included in the broad market index - GURU.Markets
Genenta Science's assets lie not in chemotherapy, but in cutting-edge genetic engineering technology that transforms a patient's own stem cells into drug-producing "factories" directly within the tumor. The company's balance sheet reflects the value of this unique platform. The chart shows the capital invested in this futuristic cancer treatment method.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Genenta Science S.p.A.
Genenta Science is an Italian biotechnology company working in the field of cancer gene therapy. Its market value is derived from its unique approach to tumor treatment. Investors are investing in its science and the hope of a breakthrough in this complex field of medicine.
Market to book capitalization ratio in a market segment - Oncology cell gene therapy
Genenta Science is an Italian biotech company developing gene therapy for cancer. Its value reflects the hope that its approach will be successful. This chart illustrates a classic pattern for the sector: a huge premium on scientific potential compared to book value.
Market to book capitalization ratio for the market as a whole
Genenta Science is an oncology company developing gene therapy. Its value is determined by the potential of this innovative technology. This chart shows how biotech market valuations are based on future scientific breakthroughs rather than current tangible assets, which contrasts sharply with the market average.
Debts of the company, segment and market as a whole
GNTA - Company debts Genenta Science S.p.A.
Genenta Science is developing gene therapy for cancer treatment. This cutting-edge field of medicine requires significant, long-term investment in research and clinical trials. This chart shows how the company is raising capital to fund its innovative platform for fighting solid tumors.
Market segment debts - Oncology cell gene therapy
Genenta Science is an Italian biotech company developing gene therapies for cancer treatment. Funding is crucial to advancing such complex technologies through clinical trials. This chart shows whether the company is following the industry-standard equity capital model to fund its cutting-edge research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Genenta Science S.p.A.
Genenta Science, a cancer gene therapy company, is an example of a company at the cutting edge of science. This chart illustrates how dependent its survival is on debt. Funding such cutting-edge research is extremely risky, and high debt means the company has very little margin for error in its scientific research.
Market segment debt to market segment book capitalization - Oncology cell gene therapy
Genenta Science is developing gene therapy for cancer using a unique approach that targets immune cells to tumors. This chart compares the debt raised for this complex research with the overall market capitalization of the entire cell and gene therapy oncology sector. It reflects the financial risks of developing breakthrough treatments.
Debt to book value of all companies in the market
Genenta Science develops gene therapy for cancer treatment, one of the most capital-intensive areas in biotech. The chart shows how the company finances its cutting-edge research. Its debt load, relative to the market, reflects both investor confidence in the technology and the high financial risks inherent in the industry.
P/E of the company, segment and market as a whole
P/E - Genenta Science S.p.A.
For Genenta Science, an Italian biotech developing cancer gene therapy, this chart represents a bet on innovation from Europe. Investors' assessment of its potential profit reflects their belief in the uniqueness of its scientific approach. The stock's performance reflects progress in clinical trials and the company's ability to compete globally.
P/E of the market segment - Oncology cell gene therapy
This chart reflects the average valuation for the speculative gene therapy sector—the benchmark for Genenta Science. The entire sector is valued based on expectations for future breakthroughs. For investors, this benchmark reflects the overall level of faith in this technology. This provides a useful framework for assessing expectations for Genenta's developments.
P/E of the market as a whole
Genenta Science is developing gene therapy for cancer. Its approach involves "teaching" immune cells to attack tumors. It's a cutting-edge, yet risky, treatment. This chart illustrates the overall interest in biotechnology, providing insight into how investors view Genenta's unique technology and its chances of success in one of the most competitive fields of medicine.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Genenta Science S.p.A.
Genenta Science is a biotech company developing gene therapy for cancer. Its approach involves "training" immune cells to fight tumors. This chart reflects analysts' expectations for this innovative technology and demonstrates their confidence in its successful clinical trials.
%20P%2FE%20Genenta%20Science%20S.p.A.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Genenta-Science-S.p.A.&v=1772641009354 "Chart of the company's future (projected) P/E Genenta Science S.p.A.")
Future (projected) P/E of the market segment - Oncology cell gene therapy
Genenta Science develops gene therapy for cancer using an approach that targets the tumor microenvironment. This chart compares its future profitability expectations with the gene therapy sector, demonstrating the level of investor confidence in its unique strategy, which could be effective in combination with other cancer treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-cell-gene-therapy&v=1772641009395 "Future (projected) P/E graph of the market segment - Oncology cell gene therapy")
Future (projected) P/E of the market as a whole
Genenta Science is a biotech company developing gene therapy for cancer. This chart shows the company's overall risk appetite. Genenta's success depends on the results of clinical trials of its innovative platform. A positive market environment is important for raising capital, but is not decisive for long-term success.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772641009453 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Genenta Science S.p.A.
Genenta Science is a biotechnology company developing gene therapy for cancer. Its approach involves "reprogramming" immune system cells to attack tumors. This chart shows the financial impact of its cutting-edge research. Current results reflect investments in preclinical and clinical programs.
Profit of companies in the market segment - Oncology cell gene therapy
Genenta Science is developing gene therapy for cancer. Its approach involves "teaching" a patient's own immune cells to attack tumors. This is a cutting-edge field in oncology. This chart shows the financial pulse of the cell and gene therapy sector, reflecting the market's confidence in the potential of these complex but promising treatments.
Overall market profit
Genenta Science is developing gene therapy for the treatment of cancer. Like other biotech companies in the research stage, its prospects depend on scientific results. Economic cycles do not affect the demand for cancer drugs, but the overall market situation, reflected here, shapes the investment climate for the entire industry.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Genenta Science S.p.A.
Genenta Science is developing an innovative gene therapy for cancer that directs immune cells directly to tumors. This is a cutting-edge scientific concept. This graph is a long-term model reflecting analysts' speculative expectations regarding the success of this complex approach.
%20profit%20of%20the%20company%20Genenta%20Science%20S.p.A.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Genenta-Science-S.p.A.&v=1772641009696 "Graph of future (projected) profit of the company Genenta Science S.p.A.")
Future (predicted) profit of companies in the market segment - Oncology cell gene therapy
Genenta Science develops gene therapy for cancer using a unique approach that "trains" immune cells to attack tumors. This chart shows forecasts for the oncogene therapy sector. Genenta's future profitability depends on the success of its cutting-edge technology in clinical trials and its potential to transform the treatment of solid tumors.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-cell-gene-therapy&v=1772641009794 "Graph of future (predicted) profits of companies in a market segment - Oncology cell gene therapy")
Future (predicted) profit of the market as a whole
Genenta Science is developing gene therapy for the treatment of cancer. The company's success depends on the results of clinical trials and its ability to attract funding. This graph, reflecting overall profit expectations, serves as a barometer of the investment climate, determining the availability of capital for cutting-edge but high-risk scientific research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772641009862 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Genenta Science S.p.A.
Genenta Science is a biotech company developing gene therapy for cancer. Its approach involves "training" immune cells to fight tumors. This chart reflects investor confidence in the future of its technology, as the company's market value is based on expectations, not revenue.
P/S market segment - Oncology cell gene therapy
Genenta Science is an Italian biopharmaceutical company developing gene therapy for solid tumors. Its approach involves "training" immune cells to attack cancer cells directly within the tumor. This chart shows the average biotech valuation, helping to understand how highly the market values this innovative and targeted therapeutic platform.
P/S of the market as a whole
Genenta Science is a biotech company developing gene therapy for cancer that "reprograms" cells to attack tumors. This graph of average market revenues contrasts sharply with Genenta's valuation, demonstrating investor confidence in the potential of its unique scientific platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Genenta Science S.p.A.
Genenta Science is developing a gene therapy for cancer based on the "Trojan horse" concept of delivering drugs directly to tumors. This chart reflects investor confidence in this innovative approach. The valuation is based on the potential future revenue from this therapy, which is currently in clinical trials.
%20P%2FS%20Genenta%20Science%20S.p.A.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Genenta-Science-S.p.A.&v=1772641009973 "The graph of the company's future (projected) P/S Genenta Science S.p.A.")
Future (projected) P/S of the market segment - Oncology cell gene therapy
Genenta Science develops gene therapy for cancer, based on "programming" cells to attack tumors. This chart compares the company's future revenue expectations with its industry sector. It reflects investor confidence in its unique scientific approach and clinical trial success.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-cell-gene-therapy&v=1772641010005 "Future (projected) P/S market segment graph - Oncology cell gene therapy")
Future (projected) P/S of the market as a whole
Genenta Science is a biotech company developing gene therapy for cancer, based on the idea of "reprogramming" immune cells to attack tumors. This graph reflects confidence in future growth, and Genenta is working at the forefront of science. The success of its approach could offer new hope for patients with solid tumors.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772641010030 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Genenta Science S.p.A.
Genenta Science is a clinical-stage biotechnology company developing gene therapies for the treatment of solid tumors. The company currently has no commercial revenue. Any revenue reflected in this chart may be from grants or funding from collaborations.
Sales of companies in the market segment - Oncology cell gene therapy
Genenta Science is a biotech company developing gene therapy for cancer. Their approach involves "training" immune cells to attack tumors. This graph illustrates the enormous potential of the oncology sector, where gene and cell therapies like Genenta's are considered the future of cancer treatment.
Overall market sales
Genenta Science S.p.A. develops gene therapy for the treatment of oncology. The company's future depends on the success of clinical trials and attracting investment. The growth in total economic revenue, reflected in this chart, creates a favorable environment for biotech funding, which is critical for Genenta's capital-intensive research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Genenta Science S.p.A.
Genenta Science S.p.A. is a biopharmaceutical company developing gene therapy that trains immune cells to attack tumors. This graph reflects analysts' expectations for the success of clinical trials of this innovative technology, aimed at treating difficult-to-treat cancers such as glioblastoma.
%20sales%20of%20the%20company%20Genenta%20Science%20S.p.A.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Genenta-Science-S.p.A.&v=1772641010228 "Schedule of future (projected) sales of the company Genenta Science S.p.A.")
Future (projected) sales of companies in the market segment - Oncology cell gene therapy
Genenta Science is developing gene therapy for cancer. Its approach involves modifying bone marrow stem cells to deliver interferon directly to tumors. This chart shows forecasts for the cell and gene therapy oncotherapy sector, illustrating how such advanced approaches are shaping the future of cancer treatment.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-cell-gene-therapy&v=1772641010302 "Schedule of future (projected) sales of companies in the market segment - Oncology cell gene therapy")
Future (projected) sales of the market as a whole
Genenta Science, a cancer gene therapy company, sees this chart as an indicator of investor appetite for breakthrough technologies. The optimistic economic forecasts reflected here create a favorable environment for funding long-term, capital-intensive research aimed at developing revolutionary treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772641010341 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Genenta Science S.p.A.
Genenta Science is a clinical-stage biotechnology company developing gene therapy for cancer. This chart shows the financial picture of a company at the forefront of science. It reflects not profits, but rather the amount of investment allocated to clinical trials to develop a breakthrough cancer treatment.
Market segment marginality - Oncology cell gene therapy
Genenta Science develops gene therapy for cancer. Their approach involves "arming" immune cells to attack tumors. Efficiency in this complex field requires optimizing R&D and manufacturing costs. The chart below shows how the company's operating model compares to other players in the cell and gene therapy space.
Market marginality as a whole
Genenta Science is developing gene therapy for cancer that aims to "reprogram" the tumor microenvironment. This chart shows current profitability, as Genenta develops an innovative approach to oncology. Their financial history is based on investing in science that can make tumors vulnerable to the immune system.
Employees in the company, segment and market as a whole
Number of employees in the company Genenta Science S.p.A.
Genenta Science is developing innovative gene therapy for cancer treatment. This chart shows the size of its team of highly qualified scientists. This growth is an important signal of the advancement of its unique technology from the lab to the clinic, a critical step for any biotech company.
Share of the company's employees Genenta Science S.p.A. within the market segment - Oncology cell gene therapy
Genenta Science develops gene therapy for cancer by "training" immune cells to attack tumors. This breakthrough technology requires the best minds. The chart shows the percentage of leading scientists Genenta has in its narrow niche of cell-based cancer therapy, a measure of its scientific leadership and potential.
Number of employees in the market segment - Oncology cell gene therapy
Genenta Science is a biotechnology company developing gene therapies for the treatment of cancer. Its staff consists of highly qualified research scientists. The graph demonstrates the growth of its intellectual capital, which directly reflects the progress in preclinical and early clinical trials of its innovative platform.
Number of employees in the market as a whole
Genenta Science develops gene therapy for the treatment of cancer. Companies at the forefront of science operate by their own rules. This graph reflects the general situation, but for Genenta, the key driver for team expansion is not the labor market, but a scientific breakthrough that could change approaches to cancer treatment.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Genenta Science S.p.A. (GNTA)
Genenta Science is another example of a biotech company whose market capitalization is based on expectations for scientific developments. This chart clearly demonstrates how the market values its pipeline. A very high ratio per employee is a classic sign of an R&D company in the pharmaceutical industry.
%20of%20the%20company%20Genenta%20Science%20S.p.A.%20(GNTA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Genenta-Science-S.p.A.-GNTA&v=1772641010667 "Chart of market capitalization per employee (in thousands of dollars) of the company Genenta Science S.p.A. (GNTA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Genenta Science develops gene therapy for cancer treatment. Like many biotech companies, its valuation is determined by the prospects for future clinical trial success. This chart shows how highly investors value Genenta's scientific potential per employee compared to its sector peers.
%20by%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-cell-gene-therapy&v=1772641010720 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology cell gene therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Genenta Science is a biotech company developing gene therapy for cancer. Its approach involves "training" immune cells to fight tumors. This chart illustrates the enormous value the market places on a cutting-edge scientific idea and the team working to bring it to life.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772641010740 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Genenta Science S.p.A. (GNTA)
Genenta Science is an Italian biotech company developing gene therapy (targeting monocytes) for cancer treatment. This is pure R&D. This graph will be negative, reflecting the amount of research investment per scientist. This is a bet that their scientific platform will lead to a breakthrough therapy.
%20Chart%20Genenta%20Science%20S.p.A.%20(GNTA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Genenta-Science-S.p.A.-GNTA&v=1772641010784 "Company Profit Per Employee (in thousands of dollars) Chart Genenta Science S.p.A. (GNTA)")
Profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Genenta Science (GNTA) is an Italian biotech company developing gene therapy for cancer. Their approach is based on hematopoietic stem cell engineering. Currently in the clinical stage, the company is focused on R&D. This chart shows how effectively the team of scientists is using capital to advance their complex platform.
%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-cell-gene-therapy&v=1772641010813 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Genenta Science is an Italian biotech company developing gene therapy for cancer treatment. This is highly complex science, requiring enormous investment. This graph shows that the company is in the early stages of R&D. Negative profit per employee is normal, as all resources are invested in the scientists who create intellectual property.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772641010985 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Genenta Science S.p.A. (GNTA)
Genenta Science is a biotech company developing gene therapy for cancer. This graph shows the company's future potential during clinical trials. Low or no revenue per employee is the norm, and any revenue will likely come from strategic partnerships that demonstrate confidence in their scientific approach.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Genenta-Science-S.p.A.-GNTA&v=1772641011046 "Sales chart per company employee Genenta Science S.p.A. (GNTA)")
Sales per employee in the market segment - Oncology cell gene therapy
Genenta Science is an Italian biotech company developing gene therapy for cancer. Their approach involves "reprogramming" cells to attack tumors. This chart shows the average revenue per employee in the sector. It demonstrates the level of productivity considered normal in this complex and capital-intensive field of oncology.
Sales per employee for the market as a whole
Genenta Science S.p.A. (GNTA) is an Italian biotechnology company developing gene therapy for cancer treatment. Their approach involves "training" a patient's own stem cells to fight tumors. They are an R&D company. This graph shows the current (zero) commercial return per scientist.
Short shares by company, segment and market as a whole
Shares shorted by company Genenta Science S.p.A. (GNTA)
Genenta Science is an Italian biotech company developing gene therapy for glioblastoma, one of the most deadly forms of cancer. The chart shows the number of investors betting that this complex technology will fail to demonstrate efficacy against such an aggressive disease, leading to trial failure.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Genenta-Science-S.p.A.-GNTA&v=1772641011169 "Short Shares Chart for the Company Genenta Science S.p.A. (GNTA)")
Shares shorted by market segment - Oncology cell gene therapy
Genenta Science is developing gene therapy for cancer by attempting to "reprogram" bone marrow cells. This graph measures the overall skepticism in the sector. Its rise indicates that investors are betting heavily against gene therapy altogether, fearing safety issues or high costs that are holding back the entire industry.
Shares shorted by the overall market
Genenta Science is developing cutting-edge gene therapy for cancer, one of the most complex and capital-intensive areas of medicine. This chart reflects the overall market sentiment. In times of pessimism, investors avoid all-or-nothing stocks. And that's precisely what companies like GNTA are, betting on a single, revolutionary, yet unproven drug.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Genenta Science S.p.A. (GNTA)
Genenta Science is developing gene therapy for cancer treatment. This is one of the most advanced, but also risky, areas in medicine. This chart measures the speed and strength of price movements, reflecting investor excitement (above 70) or disappointment (below 30) in response to clinical trial news.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Genenta-Science-S.p.A.-GNTA&v=1772641011275 "RSI 14 indicator chart for the company's stock Genenta Science S.p.A. (GNTA)")
RSI 14 Market Segment - Oncology cell gene therapy
Genenta (GNTA) is a biotech (Italy), a "Trojan horse" for cancer. Their specialty is gene therapy with stem cells, which deliver a "killer" (interferon) directly to the tumor. The "oncology cell gene therapy" (biotech) sector thrives on news. RSI\_14\_Seg shows the "temperature" of the *entire* segment. It helps us understand: is GNTA's growth due to their R&D, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
Genenta Science (GNTA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GNTA (Genenta Science S.p.A.)
Genenta Science (GNTA) is a biotech company developing gene therapy that reprograms stem cells to attack cancer tumors. This chart shows the average 12-month forecast. It reflects analysts' confidence in this innovative platform and data from its early clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GNTA-Genenta-Science-S.p.A.&v=1772641011427 "A chart showing analyst consensus forecasts for the expected stock price. GNTA (Genenta Science S.p.A.)")
The difference between the consensus estimate and the actual stock price GNTA (Genenta Science S.p.A.)
Genenta Science (GNTA) is an Italian biotech company developing gene therapy (based on stem cells) to "reprogram" the immune system to fight cancer. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their sophisticated R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GNTA-Genenta-Science-S.p.A.&v=1772641011471 "A chart showing the difference between the consensus forecast and the actual stock price. GNTA (Genenta Science S.p.A.)")
Analyst consensus forecast for stock prices by market segment - Oncology cell gene therapy
Genenta Science is an Italian biotech company developing gene therapy that "reprograms" blood stem cells to attack cancer tumors. This chart shows general expectations for the oncology sector, reflecting experts' confidence in the success of this complex R&D platform.
Analysts' consensus forecast for the overall market share price
Genenta is a clinical-stage biotech company (cell therapy). It's an R&D company that's burning cash. This chart, reflecting the market's overall risk appetite, is vital. When optimism is high, investors fund speculative research. When pessimism ("risk-off") takes over, funding for biotechs like GNTA dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Genenta Science S.p.A.
Genenta Science is an Italian biotech company working in the field of cell therapy. They develop protected stem cells that deliver therapeutic genes directly to tumors, making them visible to the immune system. This chart is a clear indicator of faith in their R&D. Its dynamics reflect the market's speculative assessment of their R&D platform and clinical trial data.
AKIMA Market Segment Index - Oncology cell gene therapy
Genenta Science (GNTA) is an Italian biotech company developing gene therapy for cancer. Their approach involves training hematopoietic stem cells to attack tumors. The chart shows the segment's average index, helping investors assess how this cutting-edge, yet very early-stage research strategy compares to the average in the cell and gene therapy sector.
The AKIM Index for the overall market
Genenta Science is an Italian biotech company, a pioneer in stem cell gene therapy for solid tumors. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for evaluating this innovative platform.
